Discovery of VU6008677: A Structurally Distinct Tricyclic M<sub>4</sub> Positive Allosteric Modulator with Improved CYP450 Profile-Reference-Cited by-同舟云学术

Discovery of VU6008677: A Structurally Distinct Tricyclic M₄ Positive Allosteric Modulator with Improved CYP450 Profile

Published:2024-07-03 Issue:8 Volume:15 Page:1358-1366
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Capstick Rory A.¹²,Bollinger Sean R.¹²,Engers Julie L.¹²,Long Madeline F.¹²^ORCID,Chang Sichen¹²,Luscombe Vincent B.¹²^ORCID,Rodriguez Alice L.¹²^ORCID,Niswender Colleen M.¹²³⁴,Bridges Thomas M.¹²,Boutaud Olivier¹²,Conn P. Jeffrey¹²³,Engers Darren W.¹²,Lindsley Craig W.¹²⁵^ORCID,Temple Kayla J.¹²^ORCID

Affiliation:

1. Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States

2. Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

3. Vanderbilt Kennedy Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

4. Vanderbilt Brain Institute, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, United States

5. Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37232, United States

Funder

Common Fund

National Institutes of Health

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.4c00249

Reference33 articles.

1. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia

2. Allosteric activation of M4 muscarinic receptors improve behavioral and physiological alterations in early symptomatic YAC128 mice

3. The antipsychotic potential of muscarinic allosteric modulation

4. Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release

5. Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia